WO2008126693A1 - ミトコンドリア障害脳疾患治療剤及び診断剤 - Google Patents

ミトコンドリア障害脳疾患治療剤及び診断剤 Download PDF

Info

Publication number
WO2008126693A1
WO2008126693A1 PCT/JP2008/055959 JP2008055959W WO2008126693A1 WO 2008126693 A1 WO2008126693 A1 WO 2008126693A1 JP 2008055959 W JP2008055959 W JP 2008055959W WO 2008126693 A1 WO2008126693 A1 WO 2008126693A1
Authority
WO
WIPO (PCT)
Prior art keywords
remedy
brain disease
diagnostic
mitochondrial dysfunction
dysfunction brain
Prior art date
Application number
PCT/JP2008/055959
Other languages
English (en)
French (fr)
Inventor
Toshihiko Kuroiwa
Yoshinaga Kajimoto
Takahiro Masubuchi
Masahiro Ishizuka
Tohru Tanaka
Original Assignee
Sbi Alapromo Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP17193845.9A priority Critical patent/EP3281642B1/en
Priority to AU2008239234A priority patent/AU2008239234B2/en
Priority to KR1020097020513A priority patent/KR101250576B1/ko
Priority to US12/594,672 priority patent/US20100120916A1/en
Priority to CA2682855A priority patent/CA2682855C/en
Priority to BRPI0810081-0A2A priority patent/BRPI0810081A2/pt
Application filed by Sbi Alapromo Co., Ltd. filed Critical Sbi Alapromo Co., Ltd.
Priority to EP08739088.6A priority patent/EP2135613B1/en
Priority to NZ580138A priority patent/NZ580138A/en
Priority to CN2008800108818A priority patent/CN101678047B/zh
Priority to KR1020127034024A priority patent/KR101383418B1/ko
Publication of WO2008126693A1 publication Critical patent/WO2008126693A1/ja
Priority to US13/613,565 priority patent/US8927532B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

　脳梗塞に代表される脳疾患の治療剤及び診断剤の提供。 （Ａ）一般式（１） 　　Ｒ2Ｒ1ＮＣＨ2ＣＯＣＨ2ＣＨ2ＣＯＲ3　　　（１） （式中、Ｒ1及びＲ2は各々独立に、水素原子、アルキル基、アシル基、アルコキシカルボニル基、アリール基又はアラルキル基を示し；Ｒ3はヒドロキシ基、アルコキシ基、アシルオキシ基、アルコキシカルボニルオキシ基、アリールオキシ基、アラルキルオキシ基又はアミノ基を示す。） で表されるδ－アミノレブリン酸、その誘導体又はそれらの塩、と（Ｂ）鉄化合物とを組み合せてなることを特徴とするミトコンドリア障害脳疾患治療剤。
PCT/JP2008/055959 2007-04-05 2008-03-27 ミトコンドリア障害脳疾患治療剤及び診断剤 WO2008126693A1 (ja)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU2008239234A AU2008239234B2 (en) 2007-04-05 2008-03-27 Remedy and diagnostic for mitochondrial dysfunction brain disease
KR1020097020513A KR101250576B1 (ko) 2007-04-05 2008-03-27 미토콘드리아 장애 뇌질환 치료제 및 진단제
US12/594,672 US20100120916A1 (en) 2007-04-05 2008-03-27 Therapeutic agent and diagnostic agent for mitochondrial dysfunction brain diseases
CA2682855A CA2682855C (en) 2007-04-05 2008-03-27 Therapeutic agent and diagnostic agent for mitochondrial dysfunction brain diseases
BRPI0810081-0A2A BRPI0810081A2 (pt) 2007-04-05 2008-03-27 Agente terapêutico e agente diagnóstico para doenças cerebrais de disfunção mitocondrial
EP17193845.9A EP3281642B1 (en) 2007-04-05 2008-03-27 Diagnostic agent for mitochondrial dysfunction brain diseases
EP08739088.6A EP2135613B1 (en) 2007-04-05 2008-03-27 Remedy for mitochondrial dysfunction brain diseases
NZ580138A NZ580138A (en) 2007-04-05 2008-03-27 THERAPEUTIC AGENT AND DIAGNOSTIC AGENT FOR MITOCHONDRIAL DYSFUNCTION BRAIN DISEASEs
CN2008800108818A CN101678047B (zh) 2007-04-05 2008-03-27 用于线粒体功能障碍性脑疾病的治疗剂和诊断剂
KR1020127034024A KR101383418B1 (ko) 2007-04-05 2008-03-27 미토콘드리아 장애 뇌질환 치료제 및 진단제
US13/613,565 US8927532B2 (en) 2007-04-05 2012-09-13 Therapeutic agent and diagnostic agent for mitochondrial dysfunction brain diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007099508A JP5098051B2 (ja) 2007-04-05 2007-04-05 ミトコンドリア障害脳疾患治療剤及び診断剤
JP2007-099508 2007-04-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/613,565 Continuation US8927532B2 (en) 2007-04-05 2012-09-13 Therapeutic agent and diagnostic agent for mitochondrial dysfunction brain diseases

Publications (1)

Publication Number Publication Date
WO2008126693A1 true WO2008126693A1 (ja) 2008-10-23

Family

ID=39863800

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/055959 WO2008126693A1 (ja) 2007-04-05 2008-03-27 ミトコンドリア障害脳疾患治療剤及び診断剤

Country Status (11)

Country Link
US (2) US20100120916A1 (ja)
EP (2) EP2135613B1 (ja)
JP (1) JP5098051B2 (ja)
KR (2) KR101383418B1 (ja)
CN (1) CN101678047B (ja)
AU (1) AU2008239234B2 (ja)
BR (1) BRPI0810081A2 (ja)
CA (1) CA2682855C (ja)
NZ (1) NZ580138A (ja)
RU (1) RU2435595C2 (ja)
WO (1) WO2008126693A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014092051A1 (ja) * 2012-12-11 2014-06-19 国立大学法人熊本大学 核磁気共鳴診断剤、及び、それを用いた、対象内の細胞、組織又は臓器の状態を検出又は診断する方法
JP2017095396A (ja) * 2015-11-24 2017-06-01 Ｓｂｉファーマ株式会社 神経発達障害改善剤
WO2018235728A1 (ja) * 2017-06-23 2018-12-27 Ｓｂｉファーマ株式会社 神経障害を改善するための医薬組成物

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102164596A (zh) * 2008-10-27 2011-08-24 Sbi5-Ala生物技术股份有限公司 以5-氨基乙酰丙酸或其衍生物、或它们的盐作为有效成分的成人病的预防、改善剂
JP5574329B2 (ja) * 2010-05-06 2014-08-20 国立大学法人 岡山大学 ミトコンドリアの蛍光染色方法
WO2012067152A1 (ja) * 2010-11-16 2012-05-24 三菱化学株式会社 Endothelial Protein C Receptor蛋白質による脳梗塞の検査方法
EP2722041B1 (en) * 2011-06-16 2018-10-24 SBI Pharmaceuticals Co., Ltd. Therapeutic agent for allergic rhinitis
JP5920901B2 (ja) * 2012-07-19 2016-05-18 Ｓｂｉファーマ株式会社 インフルエンザウイルス感染症の予防・治療剤
CN105744933A (zh) * 2013-10-29 2016-07-06 学校法人东京农业大学 共济蛋白增强剂
US10675242B2 (en) * 2016-09-02 2020-06-09 Sbi Pharmaceuticals, Co., Ltd. Aqueous formulation containing 5-aminolevulinic acid or the like
US10590496B2 (en) 2016-11-29 2020-03-17 Wedea Inc. Composition for preventing and treating degenerative brain disease using novel lactic acid bacteria
KR102007980B1 (ko) * 2016-11-29 2019-08-06 (주) 위디어 신규 유산균을 이용한 퇴행성 뇌질환 예방 및 치료용 조성물
WO2018221291A1 (ja) * 2017-05-31 2018-12-06 Ｓｂｉファーマ株式会社 過活動膀胱の予防剤または治療剤
RU2693627C2 (ru) * 2017-11-03 2019-07-03 Общество С Ограниченной Ответственностью "Валента - Интеллект" Комбинации эдаравона для лечения ишемических повреждений мозга
CN111372582A (zh) 2017-11-22 2020-07-03 康尊知识产权公司 用于治疗抑郁症和偏头痛的新化合物
TW202313061A (zh) 2018-02-05 2023-04-01 日商泰拉強石股份有限公司 包含去氮黃素并睪固酮化合物或去氮黃素并膽固醇化合物的醫藥組成物
JP6717989B2 (ja) 2018-02-05 2020-07-08 テラ・ストーン株式会社 細胞内でのａｔｐ産生を賦活するための補酵素因子の使用
WO2020125464A1 (zh) * 2018-12-20 2020-06-25 普惠德生技股份有限公司 含有亚铁胺基酸螯合物粒子的组合物用于制备治疗或减缓自体免疫相关疾病的医药品的用途
RU2744453C2 (ru) * 2019-09-02 2021-03-09 Федеральное государственное бюджетное учреждение науки Институт теоретической и экспериментальной биофизики Российской академии наук (ИТЭБ РАН) Таргетная неинвазивная трансплантация в мозг функционально активных митохондрий для лечения нейродегенеративных заболеваний
US20240082189A1 (en) * 2021-01-25 2024-03-14 Juntendo Educational Foundation Therapeutic agent for hypertrophic cardiomyopathy

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH049360A (ja) 1990-04-11 1992-01-14 Cosmo Sogo Kenkyusho:Kk ５―アミノレブリン酸アルキルエステル又はその塩及びその製造方法並びにこれを有効成分とする除草剤
EP0704209A1 (en) * 1994-09-20 1996-04-03 JOHNSON & JOHNSON MEDICAL, INC. Transdermally active pharmaceutical composition containing 5-aminolaevulinic acid
JPH11501914A (ja) 1995-03-10 1999-02-16 フォトキュアー エイエス 光化学治療における光増感剤としての５−アミノレブリン酸のエステル
JPH11116446A (ja) * 1997-10-15 1999-04-27 Shiseido Co Ltd 頭部用外用剤
JP2005314361A (ja) 2004-03-30 2005-11-10 Cosmo Oil Co Ltd ５−アミノレブリン酸硝酸塩及びその製造方法
JP2005314360A (ja) 2004-03-30 2005-11-10 Cosmo Oil Co Ltd ５−アミノレブリン酸スルホン酸塩及びその製造方法
WO2005105022A1 (ja) 2004-04-28 2005-11-10 Yoshiyasu Ito 育毛剤
JP2006182753A (ja) 2004-03-30 2006-07-13 Cosmo Oil Co Ltd ５−アミノレブリン酸リン酸塩、その製造方法及びその用途
WO2006117885A1 (ja) * 2005-04-28 2006-11-09 Cosmo Oil Co., Ltd. 皮膚外用剤
JP2007099508A (ja) 2005-10-06 2007-04-19 G D Spa 間欠動作する包装装置における製品の移送方法およびユニット

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0331665Y2 (ja) * 1984-09-05 1991-07-04
US5079262A (en) 1989-07-28 1992-01-07 Queen's University At Kingston Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid
GB9701675D0 (en) * 1997-01-28 1997-03-19 Bridgeman Keith Composition for the treatment of parkinson's disease
CA2580584C (en) * 2003-09-19 2015-07-28 Galileo Pharmaceuticals, Inc. Use of alpha-tocotrienol for treatment of mitochondrial diseases
JP5034032B2 (ja) 2004-09-29 2012-09-26 Ｓｂｉファーマ株式会社 腫瘍診断剤
EP1742038A1 (en) * 2005-07-06 2007-01-10 Academisch Medisch Centrum bij de Universiteit van Amsterdam Device and method for determining the concentration of a substance

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH049360A (ja) 1990-04-11 1992-01-14 Cosmo Sogo Kenkyusho:Kk ５―アミノレブリン酸アルキルエステル又はその塩及びその製造方法並びにこれを有効成分とする除草剤
EP0704209A1 (en) * 1994-09-20 1996-04-03 JOHNSON & JOHNSON MEDICAL, INC. Transdermally active pharmaceutical composition containing 5-aminolaevulinic acid
JPH11501914A (ja) 1995-03-10 1999-02-16 フォトキュアー エイエス 光化学治療における光増感剤としての５−アミノレブリン酸のエステル
JPH11116446A (ja) * 1997-10-15 1999-04-27 Shiseido Co Ltd 頭部用外用剤
JP2005314361A (ja) 2004-03-30 2005-11-10 Cosmo Oil Co Ltd ５−アミノレブリン酸硝酸塩及びその製造方法
JP2005314360A (ja) 2004-03-30 2005-11-10 Cosmo Oil Co Ltd ５−アミノレブリン酸スルホン酸塩及びその製造方法
JP2006182753A (ja) 2004-03-30 2006-07-13 Cosmo Oil Co Ltd ５−アミノレブリン酸リン酸塩、その製造方法及びその用途
WO2005105022A1 (ja) 2004-04-28 2005-11-10 Yoshiyasu Ito 育毛剤
WO2006117885A1 (ja) * 2005-04-28 2006-11-09 Cosmo Oil Co., Ltd. 皮膚外用剤
JP2007099508A (ja) 2005-10-06 2007-04-19 G D Spa 間欠動作する包装装置における製品の移送方法およびユニット

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NOU SHINKEI GEKA, vol. 29, no. 11, 2001, pages 1019 - 1031
See also references of EP2135613A4

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014092051A1 (ja) * 2012-12-11 2014-06-19 国立大学法人熊本大学 核磁気共鳴診断剤、及び、それを用いた、対象内の細胞、組織又は臓器の状態を検出又は診断する方法
CN104981255A (zh) * 2012-12-11 2015-10-14 国立大学法人熊本大学 核磁共振诊断剂以及使用所述核磁共振诊断剂来检测或诊断对象中细胞、组织或器官状态的方法
JP5980953B2 (ja) * 2012-12-11 2016-08-31 国立大学法人 熊本大学 核磁気共鳴診断剤、及び、それを用いた、対象内の細胞、組織又は臓器の状態を検出又は診断する方法
CN104981255B (zh) * 2012-12-11 2018-11-30 国立大学法人熊本大学 核磁共振诊断剂以及使用所述核磁共振诊断剂来检测或诊断对象中细胞、组织或器官状态的方法
US11633505B2 (en) 2012-12-11 2023-04-25 National University Corporation Kumamoto University Nuclear magnetic resonance diagnostic agent, and method for detecting or diagnosing state of cell, tissue or organ in subject using same
JP2017095396A (ja) * 2015-11-24 2017-06-01 Ｓｂｉファーマ株式会社 神経発達障害改善剤
WO2018235728A1 (ja) * 2017-06-23 2018-12-27 Ｓｂｉファーマ株式会社 神経障害を改善するための医薬組成物
JPWO2018235728A1 (ja) * 2017-06-23 2020-04-23 Ｓｂｉファーマ株式会社 神経障害を改善するための医薬組成物
JP7104037B2 (ja) 2017-06-23 2022-07-20 Ｓｂｉファーマ株式会社 神経障害を改善するための医薬組成物

Also Published As

Publication number Publication date
EP2135613B1 (en) 2017-11-22
CN101678047A (zh) 2010-03-24
EP2135613A1 (en) 2009-12-23
AU2008239234A1 (en) 2008-10-23
KR101383418B1 (ko) 2014-04-08
JP2008255059A (ja) 2008-10-23
AU2008239234B2 (en) 2012-11-08
KR20130004943A (ko) 2013-01-14
RU2435595C2 (ru) 2011-12-10
BRPI0810081A2 (pt) 2014-10-21
RU2009136582A (ru) 2011-04-10
CA2682855A1 (en) 2008-10-23
EP2135613A4 (en) 2010-07-21
CA2682855C (en) 2015-06-23
NZ580138A (en) 2011-04-29
US8927532B2 (en) 2015-01-06
US20100120916A1 (en) 2010-05-13
EP3281642A1 (en) 2018-02-14
US20130011337A1 (en) 2013-01-10
CN101678047B (zh) 2013-05-22
EP3281642B1 (en) 2019-05-01
JP5098051B2 (ja) 2012-12-12
KR101250576B1 (ko) 2013-04-03
KR20100014718A (ko) 2010-02-10

Similar Documents

Publication Publication Date Title
WO2008126693A1 (ja) ミトコンドリア障害脳疾患治療剤及び診断剤
AU2749502A (en) Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
EP1845081A4 (en) amide
HK1165954A1 (en) Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
AR057891A1 (es) Compuestos de oxazol y composicion farmaceutica
PH12014501719A1 (en) Pyridone derivatives
BR112013025881A2 (pt) composto representado pela fórmula geral (i), composto ou um sal do mesmo, inibidor deagregação tau, inibidor de b-secretase, inibidor de agregação de b-proteína amiloide, composição farmacêutica, preparação oral ou parenteral e composto representado pela fórmula geral (ii)
CY1114520T1 (el) Παραγωγο ινδολιζινης και χρηση αυτου για ιατρικους σκοπους
WO2007110237A3 (en) Amide derivatives and their application for the treatment of g protein related diseases
EP2604602A4 (en) HETEROARYLPYRAZOLDERIVAT
AR071236A1 (es) Inhibidores ciclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
GEP201706608B (en) 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases
TW200734328A (en) Aryl-isoxazolo-4-yl-imidazo [1,5-a] pyridine derivatives
MX2010003603A (es) Metodo para el tratamiento de enfermedades de riñon poliquisticas con derivados de ceramida.
WO2008105408A1 (ja) ウレイド基とアミノカルボニル基を置換基として有する新規ピロール誘導体
WO2008137816A8 (en) Tricyclic compounds as matrix metalloproteinase inhibitors
DOP2010000283A (es) Inhibidores de desacetilasas b a base de hidroxamato
TW200738651A (en) Cyclohexyl sulfonamide derivatives
DE602006008962D1 (de) Verfahren zur herstellung von valsartan
MA33618B1 (fr) Agent thérapeutique destiné aux troubles de l'humeur
WO2009013841A1 (ja) 植物における金属成分の吸収向上剤
WO2008136378A1 (ja) 新規なスルホンアミド誘導体またはその塩
WO2008090717A1 (ja) Ａｄａｍ阻害剤
WO2007119004A3 (fr) Methode de diagnostic in vitro ou ex vivo de desordres psychiatriques et/ou de dysbioses intestinales
BRPI0606659A2 (pt) processos para a preparação de álcoois aminoetoxibenzìlicos

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880010881.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08739088

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 1020097020513

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2682855

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 580138

Country of ref document: NZ

Ref document number: 2009136582

Country of ref document: RU

REEP Request for entry into the european phase

Ref document number: 2008739088

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12594672

Country of ref document: US

Ref document number: 6352/DELNP/2009

Country of ref document: IN

Ref document number: 2008739088

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008239234

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2008239234

Country of ref document: AU

Date of ref document: 20080327

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020127034024

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0810081

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20091002